Ownership and insider activity for Silo Pharma, Inc. (SILO): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Silo Pharma Inc. operates as a developmental-stage biopharmaceutical firm dedicated to creating treatments for a variety of underserviced medical conditions. These include stress-related psychiatric disorders, persistent pain syndromes, and diseases impacting the central nervous system (CNS). The company's approach combines both traditional and psychedelic therapies, with a strong emphasis on innovative formulations and advanced drug delivery systems.
Price
| Price | $1.76 |
| Market Cap | $2M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2025-12-15 | Weisblum Eric | P-Purchase | 2,500 | $1K |
| 2025-12-15 | Weisblum Eric | P-Purchase | 2,500 | $1K |
| 2025-11-21 | Weisblum Eric | P-Purchase | 1,000 | $365 |
| 2025-11-20 | Weisblum Eric | P-Purchase | 1,000 | $370 |
| 2025-11-19 | Weisblum Eric | P-Purchase | 4,500 | $2K |
| 2025-11-18 | Weisblum Eric | P-Purchase | 7,500 | $3K |
| 2025-05-27 | Weisblum Eric | P-Purchase | 10,000 | $4K |
| 2025-05-23 | Linsley Wayne | A-Award | 50,000 | $21K |
| 2025-05-23 | Munoz Kevin | A-Award | 50,000 | $21K |
| 2025-05-23 | Ryweck Daniel E. | A-Award | 50,000 | $21K |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $579209 | $294591 | $336679 | $111752 | $1.1M | $9.8M | $11.4M | $3.5M | $3.9M | $4.7M |
| Short-term Investments | 0 | 0 | $228294 | $9394 | $200 | $419995 | $3118 | $4.1M | $3.2M | $2.1M |
| Receivables | $58549 | 0 | 0 | $200000 | $23500 | 0 | $66010 | 0 | 0 | 0 |
| Inventory | 0 | 0 | $26973 | $156366 | $33484 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $664731 | $1.6M | $625977 | $493845 | $1.4M | $10.4M | $11.6M | $7.7M | $7.1M | $7.4M |
| Property, Plant & Equipment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | $29440 | 0 | 0 | 0 | 0 | 0 | $241215 | $217375 |
| Total Assets | $1.3M | $1.6M | $855417 | $493845 | $1.4M | $10.5M | $11.6M | $7.7M | $7.4M | $7.6M |
| Accounts Payable | $53098 | $38343 | $25631 | $54862 | $127069 | $417937 | $364216 | $703488 | $1.6M | $578081 |
| Short-term Debt | 0 | 0 | $22344 | $61875 | $14654 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $53098 | $38343 | $47975 | $116737 | $141723 | $490039 | $436318 | $775590 | $1.7M | $650183 |
| Long-term Debt | 0 | 0 | 0 | 0 | $4246 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $453098 | $438343 | $447975 | $516737 | $145969 | $1.4M | $1.3M | $1.6M | $2.4M | $1.3M |
| Retained Earnings | -$400000 | -$470388 | -$1.6M | -$2.7M | -$5.8M | -$3.3M | -$7.2M | -$10.9M | -$15.3M | -$19.5M |
| Total Equity | $846506 | $1.2M | $407442 | -$22892 | $1.3M | $9.1M | $10.3M | $6.2M | $5.0M | $6.3M |
| Total Debt | 0 | 0 | $22344 | $61875 | $18900 | 0 | 0 | 0 | 0 | 0 |
| Net Debt | -$579209 | -$294591 | -$542629 | -$59271 | -$1.1M | -$10.3M | -$11.4M | -$7.7M | -$7.1M | -$6.9M |
| Working Capital | $611633 | $1.6M | $578002 | $377108 | $1.3M | $9.9M | $11.1M | $6.9M | $5.5M | $6.7M |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 5.36 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -3.06 |
Profitability
| Return on Equity | -81.74% |
| Return on Invested Capital | -91.31% |
| Return on Assets | -75.13% |
| Gross Margin | -474.31% |
| Operating Margin | -8250.46% |
| Net Margin | -8269.53% |
Related companies: BDRX · CANF · CMND · CNSP · GRI · INM · JAGX
Explore sector: Healthcare · Biotechnology
More sections of SILO: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks